An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension [Studio multicentrico, randomizzato, in aperto, della durata di 8 settimane per valutare efficacia e la sicurezza di aliskiren 300 mg al giorno somministrato per via orale dopo un pasto leggero rispetto alla somministrazione a digiuno in pazienti con ipertensione].

Trial Profile

An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension [Studio multicentrico, randomizzato, in aperto, della durata di 8 settimane per valutare efficacia e la sicurezza di aliskiren 300 mg al giorno somministrato per via orale dopo un pasto leggero rispetto alla somministrazione a digiuno in pazienti con ipertensione].

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2016

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01570686).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top